Benlysta: first targeted lupus treatment

Benlysta (belimumab) is licensed as add-on therapy in patients with autoantibody-positive systemic lupus erythematosus (SLE) who have high disease activity despite standard treatment.

Benlysta must be administered in hospital
Benlysta must be administered in hospital
Belimumab is a monoclonal antibody specific for the soluble human B lymphocyte stimulator protein, BLyS. It inhibits the differentiation of B cells into antibody-producing plasma cells.1

Two pivotal randomised trials showed that the addition of belimumab to standard care improves control of disease activity in SLE.

BLISS-76 and BLISS-52 enrolled seropositive SLE patients (n=819 and n=865, respectively). In addition to standard treatment, patients received belimumab 10mg/kg or 1mg/kg or placebo by intravenous infusion on days 0, 14 and 28, and every 28 days thereafter.2,3

In both studies, response rates at week 52 (as determined by the SLE Responder Index) were significantly higher in patients treated with the 10mg/kg dose of belimumab than in patients who received placebo. In a pooled analysis of the two studies, the combined response rate was 51% for belimumab 10mg/kg compared with 39% for placebo (p<0.0001).2,3

Belimumab was well tolerated in both studies, with rates of adverse events similar to placebo.2,3


  1. Benlysta Summary of Product Characteristics, July 2011.
  2. Furie R et al. Arthritis Rheum 2011, Accepted article; DOI: 10.1002/art.30613.
  3. Navarra SV et al. Lancet 2011; 377: 721–31.

View Benlysta drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Intal asthma inhaler to be discontinued

Intal asthma inhaler to be discontinued

The asthma preventer inhaler Intal (sodium cromoglicate)...